Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 25, 2020

Millendo Therapeutics initiates first-in-human clinical trial of MLE-301

Millendo Therapeutics announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist that is being developed for the treatment of VMS, commonly known as hot flashes and night sweats, in menopausal women.

Millendo Therapeutics initiates first-in-human clinical trial of MLE-301